Table 4. Average rifapentine and moxifloxacin pharmacokinetic parameter estimates in the current study compared to other recent studies using rifapentine alone or given together with moxifloxacin.
Abbreviations: AUC0-24 = area under the concentration-time curve over 24 hours; Cmax = maximum concentration; TBTC = Tuberculosis Trials Consortium.
| Rifapentine | Moxifloxacin | |||||
|---|---|---|---|---|---|---|
| Dose | AUC0-24 (mcg*h/mL) | Cmax (mcg/mL) | Dose | AUC0-24 (mcg*h/mL) | Cmax (mcg/mL) | |
| Current Study | 300–450 mg daily | 314 | 12.1 | 400 mg daily | 28.0 | 2.5 |
| TBTC [30,36] | 450 mg daily | 285 | 13.0 | None | - | - |
| TBTC [30,36] | 600 mg daily | 320 | 15.5 | None | - | - |
| Rifaquin [34] | None | - | - | 400 mg once | 50.8 | 3.8 |
| Rifaquin [34] | 1200 mg once weekly | Not reported | Not reported | 400 mg once weekly | 46.2 | 2.9 |
| Rifaquin [34] | 900 mg twice weekly | Not reported | Not reported | 400 mg twice weekly | 45.3 | 2.8 |
| Healthy volunteers [35] | None | - | - | 400 mg daily | 41.9 | 4.0 |
| Healthy volunteers [35] | 900 mg three times weekly | 410* | 21.2 | 400 mg daily | 34.4 | 3.3 |
* AUC0-48 (mcg*h/mL)